hero-line-left hero-line-top
For Life Sciences

Bringing together healthcare innovators

Syapse partners with life sciences companies to deliver real-world evidence to support decision-making and foster collaboration among all the stakeholders working to maximize benefit for patients.


Work with us

Syapse is the preferred partner for life sciences companies looking to tap into the power of real-world data for oncology product portfolio planning, research and development, FDA submissions, and post-market analyses.

  • Research: access a web-based tool for exploring shared, de-identified data. Users can interact with real-world treatment trends, clinical characteristics, and outcomes for selected cohorts
  • Trials: identify the best sites and potential candidates for your molecularly targeted interventional trials; real-world patient distribution insights boost trial enrollment
  • Regulatory: create high quality, fully integrated clinical genomic datasets that can be used to accelerate FDA approvals
  • Commercial: access analytics dashboards and custom-designed collaborations that can guide your physician education and outreach efforts and shape post-market activities
As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients. Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care.”
Mike Nohaile
Mike Nohaile
SVP of Strategy, Commercialization, and Innovation at Amgen


Let’s talk

If you’d like to learn more about Syapse, tell us a little about yourself and we will reach out as soon as possible. 

What's new

Toft Group CEO and Founder Robin Toft Joins Syapse Board of Directors

SAN FRANCISCO, Calif., October 28, 2020 — Syapse®, a real-world evidence company accelerating the delivery of precision medicine throu…



For people with cancer — further evidence of worse outcomes due to COVID-19

“Delays in screenings, diagnosis and treatment because of the coronavirus pandemic are likely to result in thousands of “excess” deaths from the disease in coming years.” Ned Sharpless, M.D., director of the National Cancer Institute